Therapeutics: Core-binding factor β subunit (CBFB; CBF-β); myosin heavy chain 11 smooth muscle (MYH11; SMMHC); runt-related transcription factor 1 (RUNX1)


INDICATION: Acute myelogenous leukemia (AML)

In vitro, mouse and patient sample studies suggest a small molecule protein-protein inhibitor could

Read the full 185 word article

How to gain access

Continue reading with a
two-week free trial.